ZNF503 and central nervous system cancer: Kaplan–Meier survival analysis of both the TCGA and CGGA325 datasets showed that patients with high expression of ZNF503-AS2 in all glioma, GBM, and LGG had a poorer prognosis (Fig 2A and 2B).